Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Invitae introduces new patient pay program to make genetic testing more affordable, accessible

Invitae Corporation, a genetic information company, announced today the launch of its new patient pay price for its full menu of genetic tests at $475 per indication.

2 Jun 2015

Esperance announces positive results from EP-100 Phase II trial in paclitaxel-resistant ovarian cancer

Esperance Pharmaceuticals Inc. today reported positive results from a Phase II trial of lead candidate EP-100 in ovarian cancer patients resistant to paclitaxel. EP-100 is a targeted membrane-disrupting peptide designed to seek and destroy cancer cells that overexpress luteinizing hormone-releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over-expressed in a wide range of cancers.

1 Jun 2015

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Researchers from University Hospitals Case Medical Center Seidman Cancer Center and Case Western Reserve University School of Medicine will present data from several new studies, including a study evaluating a potential novel combination treatment for cancer patients with advanced solid tumors and a first-of-its-kind analysis of gene mutations in small cell lung cancer (SCLC), at the 51st American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago.

1 Jun 2015

Two grants to bolster research on why ovarian cancer is resistant to chemotherapy

Determining which strains of cancer will eventually become resistant to chemotherapy could be key in figuring out more effective and targeted forms of treatment. Finding the genes responsible for chemo-resistance is what Jeremy Chien, Ph.D., member of the Cancer Biology Program at The University of Kansas Cancer Center, is looking to do with an innovative system that draws inspiration from the early days of cancer gene research.

1 Jun 2015

New clinical studies on Myriad Genetics myChoice HRD companion diagnostic test presented at ASCO 2015

Myriad Genetics, Inc. today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill.

1 Jun 2015

Cancer genetic counselor helps patients make sense of genetics and statistics

Cancer was the second leading cause of death in the United States in 2013 and the American Cancer Society expects almost 10,000 new cases in New Mexico this year.

1 Jun 2015

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Researchers from the Abramson Cancer Center of the University of Pennsylvania and Penn's Perelman School of Medicine will present results from several clinical trials and other key studies during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 through June 2.

30 May 2015

B Floral raises awareness for Ovarian Cancer Research Fund

From Los Angeles to the Hamptons, New York's premiere floral event design company, B Floral, is giving back and helping raise awareness for Ovarian Cancer Research Fund (OCRF).

30 May 2015

Myriad Genetics announces new clinical studies on myChoice HRD companion diagnostic test at ASCO 2015

Myriad Genetics, Inc. today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill.

30 May 2015

Larger studies needed to validate multigene testing for prediction of breast cancer risk

While advances in technology have made multigene testing, or "panel testing," for genetic mutations that increase the risk of breast or other cancers an option, authors of a review published today in the New England Journal of Medicine say larger studies are needed in order to provide reliable risk estimates for counseling these patients.

29 May 2015

Array BioPharma presents clinical data of BRAF, MEK and HER2 drugs at 2015 ASCO Annual Meeting

Array BioPharma Inc. today announced presentations on encorafenib, binimetinib and selumetinib (licensed to AstraZeneca) at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29 – June 2, 2015 in Chicago, Illinois.

29 May 2015

DNA analysis reveals how ovarian cancer takes genetic twists and turns to outsmart chemotherapy

The largest complete DNA analysis of ovarian cancer in the world, published overnight in Nature, has revealed unprecedented new insight into the genetic twists and turns a deadly form of the disease takes to outsmart chemotherapy, potentially changing treatment approaches for women around the world.

29 May 2015

Researchers identify six mRNA isoforms that could be used to diagnose early-stage ovarian cancer

Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer.

26 May 2015

Clinical genomic sequencing could impact treatment decisions in advanced prostate cancer patients

An international collaboration of researchers are advancing precision medicine to men with advanced prostate cancer.

22 May 2015

Non-coding micro RNA molecule may control chemotherapy resistance among ovarian cancer patients

A molecule that helps control gene expression may play a role in controlling chemotherapy resistance among patients with the most common form of ovarian cancer.

21 May 2015

Abcodia raises £5.25 million funding to launch ovarian cancer screening test, ROCA

Abcodia today announced that it has raised £5.25 million funding from existing and new investors to bring the world’s most sensitive and specific ovarian cancer screening test, ROCA to market.

20 May 2015

Study evaluates VolitionRx's proprietary Nucleosomics platform in most prevalent cancers

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has accelerated its large independent prospective study evaluating its proprietary Nucleosomics platform at University Hospital Bonn in Germany.

13 May 2015

T cell expansion technology: an interview with Alexander Malykhin, CVPF, University of Pennsylvania

T cells are taken from the patient’s blood and then modified using lentivirus, adenovirus or RNA electroporation.

From Beckman Coulter Life Sciences - Flow Cytometry 5 May 2015

First new treatment authorised in a decade for advanced cervical cancer patients in the UK

The European Commission has licensed Avastin in combination with standard chemotherapy for the treatment of women with advanced cervical cancer. Until now, the treatment has been available ahead of licence to eligible patients in England via individual requests to the Cancer Drugs Fund (CDF).

28 Apr 2015

Vermillion reports expanded medical policy coverage of OVA1 test

Vermillion, Inc., a bio-analytical solutions company focused on gynecologic disease, today announced expanded medical policy coverage of its OVA1 test, following Blue Cross Blue Shield of Michigan's recent decision to include OVA1 in its medical policy guidelines.

28 Apr 2015

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Invitae introduces new patient pay program to make genetic testing more affordable, accessible

Esperance announces positive results from EP-100 Phase II trial in paclitaxel-resistant ovarian cancer

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Two grants to bolster research on why ovarian cancer is resistant to chemotherapy

New clinical studies on Myriad Genetics myChoice HRD companion diagnostic test presented at ASCO 2015

Cancer genetic counselor helps patients make sense of genetics and statistics

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

B Floral raises awareness for Ovarian Cancer Research Fund

Myriad Genetics announces new clinical studies on myChoice HRD companion diagnostic test at ASCO 2015

Larger studies needed to validate multigene testing for prediction of breast cancer risk

Array BioPharma presents clinical data of BRAF, MEK and HER2 drugs at 2015 ASCO Annual Meeting

DNA analysis reveals how ovarian cancer takes genetic twists and turns to outsmart chemotherapy

Researchers identify six mRNA isoforms that could be used to diagnose early-stage ovarian cancer

Clinical genomic sequencing could impact treatment decisions in advanced prostate cancer patients

Non-coding micro RNA molecule may control chemotherapy resistance among ovarian cancer patients

Abcodia raises £5.25 million funding to launch ovarian cancer screening test, ROCA

Study evaluates VolitionRx's proprietary Nucleosomics platform in most prevalent cancers

T cell expansion technology: an interview with Alexander Malykhin, CVPF, University of Pennsylvania

First new treatment authorised in a decade for advanced cervical cancer patients in the UK

Vermillion reports expanded medical policy coverage of OVA1 test

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in